Cara Therapeutics Inc (NASDAQ:CARA) CFO Mani Mohindru sold 4,755 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $17.05, for a total value of $81,072.75. Following the completion of the sale, the chief financial officer now directly owns 22,196 shares of the company’s stock, valued at $378,441.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

NASDAQ CARA opened at $16.76 on Friday. Cara Therapeutics Inc has a one year low of $12.19 and a one year high of $27.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.21 and a quick ratio of 4.21. The firm has a market cap of $670.67 million, a P/E ratio of -8.13 and a beta of 2.30. The stock’s 50-day moving average is $21.33 and its 200-day moving average is $21.58.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.15). Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. The business had revenue of $5.79 million during the quarter, compared to analyst estimates of $5.56 million. Equities analysts anticipate that Cara Therapeutics Inc will post -2.55 EPS for the current year.

CARA has been the topic of several recent analyst reports. ValuEngine raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 target price on shares of Cara Therapeutics in a research note on Tuesday. Cantor Fitzgerald increased their target price on shares of Cara Therapeutics from $29.00 to $33.00 in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Tuesday. Finally, BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Cara Therapeutics presently has an average rating of “Buy” and an average target price of $27.54.

A number of hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY lifted its stake in Cara Therapeutics by 16.2% in the third quarter. Metropolitan Life Insurance Co NY now owns 13,220 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 1,846 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cara Therapeutics during the third quarter worth $190,000. Barclays PLC raised its holdings in shares of Cara Therapeutics by 91.6% during the third quarter. Barclays PLC now owns 58,527 shares of the biopharmaceutical company’s stock worth $1,070,000 after acquiring an additional 27,977 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Cara Therapeutics during the third quarter worth $2,780,000. Finally, Penserra Capital Management LLC bought a new stake in Cara Therapeutics in the 3rd quarter valued at $180,000. Hedge funds and other institutional investors own 76.08% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Market Timing – The Benefits and the Danger

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.